Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (CAR-LMC)

Centre Hospitalier Universitaire de Besancon

Status

Completed

Conditions

Chronic Myeloid Leukemia

Treatments

Other: biological samples

Study type

Interventional

Funder types

Other

Identifiers

NCT02842320

P/2015/244

Details and patient eligibility

About

The tyrosine kinase inhibitor therapy (iTKs) is the first-line treatment of chronic myelogenous leukemia (CML).

Its effectiveness in controlling the progression of the disease is such that it is possible today to consider stopping treatment in patients with deep molecular response (> RM4.0).

Only in about 50% of cases, patients relapse. It has been shown in these patients that hematopoietic stem cells (HSCs) are persistant, quiescent and insensitive to iTKs. These cells are probably at the origin of relapse. It is therefore necessary to develop complementary therapies to cure the disease and consider discontinuation iTKs The development of anti-tumor immunotherapy approach using genetically modified T cells to express a chimeric antigen receptor (CAR) and specifically targeting CML CSH + could address this issue. The membrane expression of the IL-1-RAP protein could be an interesting target.

Enrollment

53 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients for whom there is a strong suspicion of CML diagnosed as part of routine activity.
written informed consent

Exclusion criteria

patient with atypical CML
patient with a non SMP CML
patients previously treated with interferon
patient enrolled in another study therapy or within the exclusion period thereof
pregnant or breast-feeding women
patient under guardianship, curator or under the protection of justice.